Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib

Overview of attention for article published in Breast Cancer Research and Treatment, July 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 2 X users

patent: 7 patents

Citations

dimensions_citation: 154 Dimensions

Readers on

mendeley: 245 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 7 patents that reference this research output.

PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND…

Application EP-4023235-A4

European Patent Office

Treatment of breast cancer using combination therapies comprising an ATP competitive AKT…

Grant US-11576919-B2

United States of America

COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER

Application EP-3849550-A4

European Patent Office

Pyridylamino substituted heterotricyclic compounds, and preparation method and…

Grant US-11168088-B2

United States of America

TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT…

Application WO-2021030248-A1

World Intellectual Property Organisation (WIPO)

Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same…

Grant US-10570141-B2

United States of America

SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME…

Application US-20190300533-A1

United States of America